Beata Śpiewankiewicz

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

Ganna Chornokur, Hui‐Yi Lin, Jonathan P. Tyrer et al. · PLoS ONE · 2015 · 906 citations · Full text

Medicine, Genetics, Oncology +17

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15

Ovarian small cell carcinoma of hypercalcemic type – evidence of germline origin and smarca4 gene inactivation. a pilot study

Jolanta Kupryjańczyk, Agnieszka Dansonka‐Mieszkowska, Joanna Moes-Sosnowska et al. · Polish Journal of Pathology · 2013 · 116 citations · Full text

Veterinary Medicine, Oncology, Pathology +17

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31

Jennifer Permuth‐Wey, Kate Lawrenson, Howard C. Shen et al. · Nature Communications · 2013 · 110 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17